---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-019381"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2022-07-15T23:59:59+00:00"
generated_at: "2026-06-24T14:39:47.619824+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncotelic presents Phase 1/2 OT-101 pancreatic cancer data; median OS doubled in patients receiving subsequent chemo

## Summary
- 55% of OT-101-treated pancreatic cancer patients had long-term disease control (21 of 37 pts).
- Median OS doubled to 9.3 vs 2.6 months (p<0.0001) for those who received subsequent chemotherapy.
- High AUC associated with improved OS: 9.6 vs 2.4 months (p=0.0006).
- OT-101 PK dose proportional (p<0.0001).
- Presentation from JCA-AACR conference available on company website and YouTube.

## SEC filing metadata
- accession: 0001493152-22-019381
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2022-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315222019381/0001493152-22-019381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315222019381/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-019381
- JSON: https://secwatch.observer/filing/0001493152-22-019381.json
- Plain text: https://secwatch.observer/filing/0001493152-22-019381.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.